The glucosamine controversy; a pharmacokinetic issue

Journal of Pharmacy and Pharmaceutical Sciences

Volumn 14, Issue 2, 2011, Pages 264-273

  Aghazadeh Habashi, Ali ^a   Jamali, Fakhreddin ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2; GLUCOSAMINE; GLUCOSAMINE SULFATE; MATRIX METALLOPROTEINASE; NITRIC OXIDE; PLACEBO;

ADJUVANT ARTHRITIS; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CRYSTAL STRUCTURE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG EXCRETION; DRUG HALF LIFE; DRUG POTENCY; DRUG STRUCTURE; DRUG TARGETING; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; OSTEOARTHRITIS; OUTCOME ASSESSMENT; RHEUMATOID ARTHRITIS; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 79961164393     PISSN: None     EISSN: 14821826     Source Type: Journal    
DOI: 10.18433/J3XG6F     Document Type: Article

References (68)

1. Byrne J. Glucosamine market reaching maturity 5-Apr-2010; http://www.nutraingredients-usa.com/Industry/Glucosamine-market-reaching-maturity, 2010.
2. Tat SK, Pelletier JP, Verges J, Lajeunesse D, Montell E, Fahmi H, et al. Chondroitin and glucosamine sulfate in combination decrease the pro-resorptive properties of human osteoarthritis subchondral bone osteoblasts: a basic science study. Arthritis Res Ther 2007;9(6):R117.
3. Bruyere O, Reginster JY. Glucosamine and chondroitin sulfate as therapeutic agents for knee and hip osteoarthritis. Drugs Aging 2007;24(7):573-80.
4. Richy F, Bruyere O, Ethgen O, Cucherat M, Henrotin Y, Reginster JY. Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis. Arch Intern Med 2003 Jul 14;163(13):1514-22.
5. Towheed TE, Anastassiades T. Glucosamine therapy for osteoarthritis: an update. J Rheumatol 2007 Sep;34(9):1787-1790.
6. Wandel S, Juni P, Tendal B, Nuesch E, Villiger PM, Welton NJ, et al. Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ 2010 Sep 16;341:c4675.
7. Bruyere O, Pavelka K, Rovati LC, Gatterova J, Giacovelli G, Olejarova M, et al. Total joint replacement after glucosamine sulphate treatment in knee osteoarthritis: results of a mean 8-year observation of patients from two previous 3-year, randomised, placebo-controlled trials. Osteoarthritis Cartilage 2008 Feb;16(2).:254-60.
8. Sawitzke AD, Shi H, Finco MF, Dunlop DD, Bingham CO, 3rd, Harris CL, et al. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trial. Arthritis Rheum 2008 Oct;58(10):3183-91.
9. Hughes R, Carr A. A randomized, double-blind, placebo-controlled trial of glucosamine sulphate as an analgesic in osteoarthritis of the knee. Rheumatology (Oxford) 2002 Mar;41(3):279-284.
10. Cibere J, Thorne A, Kopec JA, Singer J, Canvin J, Robinson DB, et al. Glucosamine sulfate and cartilage type II collagen degradation in patients with knee osteoarthritis: randomized discontinuation trial results employing biomarkers. J Rheumatol 2005 May;32(5):896-902.
11. Cibere J, Kopec JA, Thorne A, Singer J, Canvin J, Robinson DB, et al. Randomized, double-blind, placebo-controlled glucosamine discontinuation trial in knee osteoarthritis. Arthritis Rheum 2004 Oct 15;51(5):738-745.
12. Vlad SC, LaValley MP, McAlindon TE, Felson DT. Glucosamine for pain in osteoarthritis: why do trial results differ? Arthritis Rheum 2007 Jul;56(7):2267-77.
13. Block JA, Oegema TR, Sandy JD, Plaas A. The effects of oral glucosamine on joint health: is a change in research approach needed? Osteoarthritis Cartilage 2010; 18:5-11.
14. Miller KL, Clegg DO. Glucosamine and chondroitin sulfate. Rheum Dis Clin North Am 2011 Feb;37(1):103-118.
15. Lin YC, Liang YC, Sheu MT, Lin YC, Hsieh MS, Chen TF, et al. Chondroprotective effects of glucosamine involving the p38 MAPK and Akt signaling pathways. Rheumatol Int 2008 Aug;28(10):1009-1016.
16. Kim MM, Mendis E, Rajapakse N, Kim SK. Glucosamine sulfate promotes osteoblastic differentiation of MG-63 cells via anti-inflammatory effect. Bioorg Med Chem Lett 2007 Apr 1;17(7):1938-42.
17. Mendis E, Kim MM, Rajapakse N, Kim SK. The inhibitory mechanism of a novel cationic glucosamine derivative against MMP-2 and MMP-9 expressions. Bioorg Med Chem Lett 2009 May 15;19(10):2755-2759.
18. Rajapakse N, Kim MM, Mendis E, Kim SK. Inhibition of free radical-mediated oxidation of cellular biomolecules by carboxylated chitooligosaccharides. Bioorg Med Chem 2007 Jan 15;15(2):997-1003.
19. Rajapakse N, Mendis E, Kim MM, Kim SK. Sulfated glucosamine inhibits MMP-2 and MMP-9 expressions in human fibrosarcoma cells. Bioorg Med Chem 2007 Jul 15;15(14):4891-4896.
20. Hong H, Park YK, Choi MS, Ryu NH, Song DK, Suh SI, et al. Differential down-regulation of COX-2 and MMP-13 in human skin fibroblasts by glucosamine-hydrochloride. J Dermatol Sci 2009 Oct;56(1):43-50.
21. Rafi MM, Yadav PN, Rossi AO. Glucosamine inhibits LPS-induced COX-2 and iNOS expression in mouse macrophage cells (RAW 264.7) by inhibition of p38-MAP kinase and transcription factor NF-kappaB. Mol Nutr Food Res 2007 May;51(5):587-593.
22. Chan PS, Caron JP, Orth MW. Effects of glucosamine and chondroitin sulfate on bovine cartilage explants under long-term culture conditions. Am J Vet Res 2007 Jul;68(7):709-715.
23. Neil KM, Orth MW, Coussens PM, Chan PS, Caron JP. Effects of glucosamine and chondroitin sulfate on mediators of osteoarthritis in cultured equine chondrocytes stimulated by use of recombinant equine interleukin-1beta. Am J Vet Res 2005 Nov;66(11):1861-1869.
24. Nakamura H, Shibakawa A, Tanaka M, Kato T, Nishioka K. Effects of glucosamine hydrochloride on the production of prostaglandin E2, nitric oxide and metalloproteases by chondrocytes and synoviocytes in osteoarthritis. Clin Exp Rheumatol 2004 May-Jun;22(3):293-299.
25. Largo R, Alvarez-Soria MA, Diez-Ortego I, Calvo E, Sanchez-Pernaute O, Egido J, et al. Glucosamine inhibits IL-1beta-induced NFkappaB activation in human osteoarthritic chondrocytes. Osteoarthritis Cartilage 2003 Apr;11(4):290-298.
26. Chang YH, Horng CT, Chen YH, Chen PL, Chen CL, Liang CM, et al. Inhibitory effects of glucosamine on endotoxin-induced uveitis in Lewis rats. Invest Ophthalmol Vis Sci 2008 Dec;49(12):5441-5449.
27. Ali AA, Lewis SM, Badgley HL, Allaben WT, Leakey JE. Oral glucosamine increases expression of transforming growth factor beta1 (TGFbeta1) and connective tissue growth factor (CTGF) mRNA in rat cartilage and kidney: Implications for human efficacy and toxicity. Arch Biochem Biophys 2011; 510:11-8.
28. Hua J, Suguro S, Hirano S, Sakamoto K, Nagaoka I. Preventive actions of a high dose of glucosamine on adjuvant arthritis in rats. Inflamm Res 2005 Mar;54(3):127-32.
29. Kim EY, Moudgil KD. The determinants of susceptibility/resistance to adjuvant arthritis in rats. Arthritis Res Ther 2009;11(4):239.
30. Tiraloche G, Girard C, Chouinard L, Sampalis J, Moquin L, Ionescu M, et al. Effect of oral glucosamine on cartilage degradation in a rabbit model of osteoarthritis. Arthritis Rheum 2005 Apr;52(4):1118-1128.
31. Oegema TR, Jr, Deloria LB, Sandy JD, Hart DA. Effect of oral glucosamine on cartilage and meniscus in normal and chymopapain-injected knees of young rabbits. Arthritis Rheum 2002 Sep;46(9):2495-2503.
32. Wang SX, Laverty S, Dumitriu M, Plaas A, Grynpas MD. The effects of glucosamine hydrochloride on subchondral bone changes in an animal model of osteoarthritis. Arthritis Rheum 2007 May;56(5):1537-1548.
33. Wen ZH, Tang CC, Chang YC, Huang SY, Hsieh SP, Lee CH, et al. Glucosamine sulfate reduces experimental osteoarthritis and nociception in rats: association with changes of mitogen-activated protein kinase in chondrocytes. Osteoarthritis Cartilage 2010 Sep;18(9):1192-1202.
34. Kobayashi T, Notoya K, Nakamura A, Akimoto K. Fursultiamine, a vitamin B1 derivative, enhances chondroprotective effects of glucosamine hydrochloride and chondroitin sulfate in rabbit experimental osteoarthritis. Inflamm Res 2005 Jun;54(6):249-255.
35. Naito K, Watari T, Furuhata A, Yomogida S, Sakamoto K, Kurosawa H, et al. Evaluation of the effect of glucosamine on an experimental rat osteoarthritis model. Life Sci 2010 Mar 27;86(13-14):538-543.
36. Reginster JY, Richy F, Bruyere O. [Glucosamine as a pain-modifying drug in osteorthritis. What's new in 2006]. Rev Med Liege 2006 Mar;61(3):169-72.
37. Clegg DO, Reda DJ, Harris CL, Klein MA, O'Dell JR, Hooper MM, et al. Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis. N Engl J Med 2006 Feb 23;354(8):795-808.
38. McAlindon T, Formica M, LaValley M, Lehmer M, Kabbara K. Effectiveness of glucosamine for symptoms of knee osteoarthritis: results from an internet-based randomized double-blind controlled trial. Am J Med 2004 Nov 1;117(9):643-649.
39. Towheed TE, Maxwell L, Anastassiades TP, Shea B, Houpt J, Robinson V, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev 2005(2):CD002946.
40. Pelletier JP, Hochberg MC, du Souich P, Kahan A, Michel BA. Glucosamine and osteoarthritis. Effect size is encouraging. BMJ 2010 Nov 9;341:c6328.
41. Giacovelli G, Rovati LC. Glucosamine and osteoarthritis. Conclusions not supported by methods and results. BMJ 2010 Nov 9;341:c6338.
42. Noack W, Fischer M, Forster KK, Rovati LC, Setnikar I. Glucosamine sulfate in osteoarthritis of the knee. Osteoarthritis Cartilage 1994 Mar;2(1):51-9.
43. Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet 2001 Jan 27;357(9252):251-6.
44. Pavelka K, Gatterova J, Olejarova M, Machacek S, Giacovelli G, Rovati LC. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med 2002 Oct 14;162(18):2113-23.
45. Herrero-Beaumont G, Ivorra JA, Del Carmen Trabado M, Blanco FJ, Benito P, Martin-Mola E, et al. Glucosamine sulfate in the treatment of knee osteoarthritis symptoms: a randomized, double-blind, placebo-controlled study using acetaminophen as a side comparator. Arthritis Rheum 2007 Feb;56(2):555-567.
46. Sawitzke AD, Shi H, Finco MF, Dunlop DD, Harris CL, Singer NG, et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT. Ann Rheum Dis 2010 Aug;69(8):1459-1464.
47. Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ 2002 Sep 21;325(7365):619.
48. Tilburt JC, Emanuel EJ, Miller FG. Does the evidence make a difference in consumer behavior? Sales of supplements before and after publication of negative research results. J Gen Intern Med 2008 Sep;23(9):1495-1498.
49. Russell AS, Aghazadeh-Habashi A, Jamali F. Active ingredient consistency of commercially available glucosamine sulfate products. J Rheumatol 2002 Nov;29(11):2407-9.
50. Rozendaal RM, Uitterlinden EJ, van Osch GJ, Garling EH, Willemsen SP, Ginai AZ, et al. Effect of glucosamine sulphate on joint space narrowing, pain and function in patients with hip osteoarthritis; subgroup analyses of a randomized controlled trial. Osteoarthritis Cartilage 2009 Apr;17(4):427-432.
51. Rozendaal RM, Koes BW, van Osch GJ, Uitterlinden EJ, Garling EH, Willemsen SP, et al. Effect of glucosamine sulfate on hip osteoarthritis: a randomized trial. Ann Intern Med 2008 Feb 19;148(4):268-277.
52. Biggee BA, Blinn CM, McAlindon TE, Nuite M, Silbert JE. Low levels of human serum glucosamine after ingestion of glucosamine sulphate relative to capability for peripheral effectiveness. Ann Rheum Dis 2006 Feb;65(2):222-6.
53. Zhang LJ, Huang TM, Fang XL, Li XN, Wang QS, Zhang ZW, et al. Determination of glucosamine sulfate in human plasma by precolumn derivatization using high performance liquid chromatography with fluorescence detection: its application to a bioequivalence study. J Chromatogr B Analyt Technol Biomed Life Sci 2006 Sep 14;842(1):8-12.
54. Zhu Y, Zou J, Xiao D, Fan H, Yu C, Zhang J, et al. Bioequivalence of two formulations of glucosamine sulfate 500-mg capsules in healthy male Chinese volunteers: an open-label, randomized-sequence, single-dose, fasting, two-way crossover study. Clin Ther 2009 Jul;31(7):1551-1558.
55. Akarasereenont P, Chatsiricharoenkul S, Pongnarin P, Sathirakul K, Kongpatanakul S. Bioequivalence study of 500 mg glucosamine sulfate in Thai healthy volunteers. J Med Assoc Thai 2009 Sep;92(9):1234-1239.
56. Persiani S, Roda E, Rovati LC, Locatelli M, Giacovelli G, Roda A. Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man. Osteoarthritis Cartilage 2005 Dec;13(12):1041-9.
57. Jackson CG, Plaas AH, Sandy JD, Hua C, Kim-Rolands S, Barnhill JG, et al. The human pharmacokinetics of oral ingestion of glucosamine and chondroitin sulfate taken separately or in combination. Osteoarthritis Cartilage 2010 Mar;18(3):297-302.
58. Aghazadeh-Habashi A, Sattari S, Pasutto F, Jamali F. Single dose pharmacokinetics and bioavailability of glucosamine in the rat. J Pharm Pharm Sci 2002 May-Aug;5(2):181-4.
59. Ibrahim A, Jamali F, Improved Sensitive High Performance Liquid Chromatography Assay for Glucosamine in Human and Rat Biological Samples with Fluorescence Detection. Journal of Pharmacy & Pharmaceutical Sciences 2010;13(2):128.
60. Meulyzer M, Vachon P, Beaudry F, Vinardell T, Richard H, Beauchamp G, et al. Comparison of pharmacokinetics of glucosamine and synovial fluid levels following administration of glucosamine sulphate or glucosamine hydrochloride. Osteoarthritis Cartilage 2008 Sep;16(9):973-979.
61. Guan Y, Tian Y, Li Y, Yang Z, Jia Y, Hang T, et al. Application of a liquid chromatographic/tandem mass spectrometric method to a kinetic study of derivative glucosamine in healthy human urine. J Pharm Biomed Anal 2011 Apr 28;55(1):181-186.
62. Aghazadeh-Habashi A, Sattari S, Pasutto F, Jamali F. High performance liquid chromatographic determination of glucosamine in rat plasma. J Pharm Pharm Sci 2002 May-Aug;5(2):176-80.
63. Setnikar I, Palumbo R, Canali S, Zanolo G. Pharmacokinetics of glucosamine in man. Arzneimittelforschung 1993 Oct;43(10):1109-13.
64. Emami J, Pasutto FM, Jamali F. Effect of experimental diabetes mellitus and arthritis on the pharmacokinetics of hydroxychloroquine enantiomers in rats. Pharm Res 1998 Jun;15(6):897-903.
65. Piquette-Miller M, Jamali F. Influence of severity of inflammation on the disposition kinetics of propranolol enantiomers in ketoprofen-treated and untreated adjuvant arthritis. Drug Metab Dispos 1995 Feb;23(2):240-5.
66. Guirguis MS, Sattari S, Jamali F. Pharmacokinetics of celecoxib in the presence and absence of interferon-induced acute inflammation in the rat: application of a novel HPLC assay. J Pharm Pharm Sci 2001 Jan-Apr;4(1):1-6.
67. Ilic MZ, Martinac B, Handley CJ. Effects of long-term exposure to glucosamine and mannosamine on aggrecan degradation in articular cartilage. Osteoarthritis Cartilage 2003 Aug;11(8):613-622.
68. Altman RD. Glucosamine therapy for knee osteoarthritis: pharmacokientic considerations. Expert Rev Clin Pharmacol 2009;2(4):359-371.